	US 12,031,148 B2
	RNA adeno-associated virus (RAAV) vector and uses thereof
Linyu Shi, Singapore (SG); and Weiya Bai, Singapore (SG)
Assigned to HUIDAGENE THERAPEUTICS (SINGAPORE) PTE. LTD., Singapore (SG)
Filed by Huidagene Therapeutics Pte., Ltd., Singapore (SG)
Filed on Jun. 9, 2022, as Appl. No. 17/836,222.
Application 17/836,222 is a continuation of application No. PCT/CN2022/075366, filed on Feb. 7, 2022.
Claims priority of application No. PCT/CN2021/075874 (WO), filed on Feb. 7, 2021.
Prior Publication US 2023/0062529 A1, Mar. 2, 2023
Int. Cl. C12N 15/90 (2006.01); C12N 15/10 (2006.01); C12N 15/86 (2006.01)

CPC C12N 15/902 (2013.01) [C12N 15/102 (2013.01); C12N 15/86 (2013.01); C12N 2310/20 (2017.05); C12N 2750/14143 (2013.01)]

45 Claims

1. A ribonucleotide (RNA) sequence capable of being packaged into a DNA virus viral particle, wherein said RNA sequence comprises:

(1) an RNA sequence of interest (RSI); and,

(2) an RNA-packaging signal (RPS) capable of binding directly or indirectly to an RPS-interacting molecule that facilitates packaging of the RNA sequence into the DNA virus viral particle.